Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough.
In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders.
01:05 Mercier’s role at Gilead
03:05 Work-life balance and managing energy
05:10 Mercier’s biology and business background
06:02 Personal motivation and prioritizing patients
08:10 Balancing profits with patients
09:04 Public trust
11:03 Resilience following failure
13:02 Drug pricing agreements with the federal government
14:33 Growth engines for Gilead
15:24 Gilead’s billion-dollar acquisition strategy
17:24 Gilead’s COVID-19 and SARS pivot
18:07 Gilead’s AI strategy
21:34 Responsible AI use
22:10 AI-powered predictive analytics
23:07 Mercier’s leadership strategy
24:24 Ending HIV
25:30 Rapid-fire questions
30:45 Outro
Learn more about your ad choices. Visit megaphone.fm/adchoices